Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2018

Open Access 01-12-2018 | Research article

Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany

Authors: Helmuth G. Dörr, Hartmut A. Wollmann, Berthold P. Hauffa, Joachim Woelfle, on behalf of the German Society of Pediatric Endocrinology and Diabetology

Published in: BMC Endocrine Disorders | Issue 1/2018

Login to get access

Abstract

Background

Adrenal crises in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH) are life-threatening and have the potential to death.

Methods

A survey was performed among Paediatric Endocrinologists in Germany to report on deceased children with CAH. Our survey covered the whole of Germany.

Results

The participating centres reported 14 cases of death (9 female, 5 male) from 1973 until 2004, but no deaths thereafter. 11 children had the SW form and 3 the simple virilizing (SV) form. All patients were on glucocorticoid replacement, and the SW forms additionally on mineralocorticoid replacement. The age at death varied between 6 weeks and 16.5 years. Seven children died before introduction of general neonatal screening, and 7 children thereafter. Before death, the clinical signs of impending crisis were nonspecific. Five patients developed hypoglycaemia and convulsions with cerebral oedema. Half of the deceased patients died at home. The hydrocortisone dosage was only doubled in two of the 14 cases.

Conclusions

According to the assessments by the attending centres, almost all deaths could be related to an inadequate administration of stress doses of hydrocortisone. Since no deceased CAH children were reported in Germany from 2005 on, we assume the effectiveness of educational programs over the past years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update. 2004;10(6):469–85.CrossRefPubMed Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update. 2004;10(6):469–85.CrossRefPubMed
2.
go back to reference Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81–151.CrossRefPubMed Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32(1):81–151.CrossRefPubMed
5.
go back to reference Tajima T, Fujikura K, Fukushi M, Hotsubo T, Mitsuhashi Y. Neonatal screening for congenital adrenal hyperplasia in Japan. Pediatr Endocrinol Rev. 2012;10(Suppl 1):72–8.PubMed Tajima T, Fujikura K, Fukushi M, Hotsubo T, Mitsuhashi Y. Neonatal screening for congenital adrenal hyperplasia in Japan. Pediatr Endocrinol Rev. 2012;10(Suppl 1):72–8.PubMed
6.
go back to reference van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2004;151(Suppl 3):U71–5.CrossRefPubMed van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2004;151(Suppl 3):U71–5.CrossRefPubMed
7.
go back to reference White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009;5(9):490–8.CrossRefPubMed White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009;5(9):490–8.CrossRefPubMed
8.
9.
go back to reference Speiser PW. Medical treatment of classic and nonclassic congenital adrenal hyperplasia. Adv Exp Med Biol. 2011;707:41–5.CrossRefPubMed Speiser PW. Medical treatment of classic and nonclassic congenital adrenal hyperplasia. Adv Exp Med Biol. 2011;707:41–5.CrossRefPubMed
10.
go back to reference Riepe FG. Adrenal gland: congenital adrenal hyperplasia: new treatment guidelines. Nat Rev Endocrinol. 2011;7(1):6–8.CrossRefPubMed Riepe FG. Adrenal gland: congenital adrenal hyperplasia: new treatment guidelines. Nat Rev Endocrinol. 2011;7(1):6–8.CrossRefPubMed
11.
12.
go back to reference Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab. 2009;23(2):193–208.CrossRefPubMed Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab. 2009;23(2):193–208.CrossRefPubMed
13.
go back to reference Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR. Congenital adrenal hyperplasia--pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther. 2011;132(1):1–14.CrossRefPubMed Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ, Hermus AR. Congenital adrenal hyperplasia--pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther. 2011;132(1):1–14.CrossRefPubMed
14.
go back to reference Odenwald B, Nennstiel-Ratzel U, Dorr HG, Schmidt H, Wildner M, Bonfig W. Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life. Eur J Endocrinol. 2016;174(2):177–86.PubMedCrossRef Odenwald B, Nennstiel-Ratzel U, Dorr HG, Schmidt H, Wildner M, Bonfig W. Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life. Eur J Endocrinol. 2016;174(2):177–86.PubMedCrossRef
15.
go back to reference Reisch N, Willige M, Kohn D, Schwarz HP, Allolio B, Reincke M, Quinkler M, Hahner S, Beuschlein F. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012;167:35–42.CrossRefPubMed Reisch N, Willige M, Kohn D, Schwarz HP, Allolio B, Reincke M, Quinkler M, Hahner S, Beuschlein F. Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol. 2012;167:35–42.CrossRefPubMed
16.
go back to reference Falhammar H, Frisen L, Norrby C, Hirschberg AL, Almqvist C, Nordenskjold A, Nordenstrom A. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014;99(12):E2715–21.CrossRefPubMed Falhammar H, Frisen L, Norrby C, Hirschberg AL, Almqvist C, Nordenskjold A, Nordenstrom A. Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2014;99(12):E2715–21.CrossRefPubMed
17.
go back to reference Cleveland WW, Green OC, Wilkins L. Deaths in congenital adrenal hyperplasia. Pediatrics. 1962;29:3–17.PubMed Cleveland WW, Green OC, Wilkins L. Deaths in congenital adrenal hyperplasia. Pediatrics. 1962;29:3–17.PubMed
18.
go back to reference Lim YJ, Batch JA, Warne GL. Adrenal 21-hydroxylase deficiency in childhood: 25 years' experience. J Paediatr Child Health. 1995;31(3):222–7.CrossRefPubMed Lim YJ, Batch JA, Warne GL. Adrenal 21-hydroxylase deficiency in childhood: 25 years' experience. J Paediatr Child Health. 1995;31(3):222–7.CrossRefPubMed
19.
go back to reference Thilen A, Larsson A. Congenital adrenal hyperplasia in Sweden 1969-1986. Prevalence, symptoms and age at diagnosis. Acta Paediatr Scand. 1990;79(2):168–75.CrossRefPubMed Thilen A, Larsson A. Congenital adrenal hyperplasia in Sweden 1969-1986. Prevalence, symptoms and age at diagnosis. Acta Paediatr Scand. 1990;79(2):168–75.CrossRefPubMed
20.
go back to reference Krone N, Roscher AA, Schwarz HP, Braun A. Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. Clin Chem. 1998;44(10):2075–82.PubMed Krone N, Roscher AA, Schwarz HP, Braun A. Comprehensive analytical strategy for mutation screening in 21-hydroxylase deficiency. Clin Chem. 1998;44(10):2075–82.PubMed
21.
go back to reference Swerdlow AJ, Higgins CD, Brook CG, Dunger DB, Hindmarsh PC, Price DA, Savage MO. Mortality in patients with congenital adrenal hyperplasia: a cohort study. J Pediatr. 1998;133(4):516–20.CrossRefPubMed Swerdlow AJ, Higgins CD, Brook CG, Dunger DB, Hindmarsh PC, Price DA, Savage MO. Mortality in patients with congenital adrenal hyperplasia: a cohort study. J Pediatr. 1998;133(4):516–20.CrossRefPubMed
22.
go back to reference Jaaskelainen VR. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr. 2000;89(2):183–7.CrossRefPubMed Jaaskelainen VR. Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr. 2000;89(2):183–7.CrossRefPubMed
23.
go back to reference Ogawa E, Fujieda K, Tachibana K, Inomata H, Kinoshita E, Kusuda S, Nishi Y, Okada T, Saisho S, Tajima T, et al. Mortaility in patients with congenital 21-.Hydroxylase deficiency diagnosed after the introduction of a newborn screening program in Japan. Clin Pediatr Endocrinology. 2003;12(1):19–23.CrossRef Ogawa E, Fujieda K, Tachibana K, Inomata H, Kinoshita E, Kusuda S, Nishi Y, Okada T, Saisho S, Tajima T, et al. Mortaility in patients with congenital 21-.Hydroxylase deficiency diagnosed after the introduction of a newborn screening program in Japan. Clin Pediatr Endocrinology. 2003;12(1):19–23.CrossRef
24.
go back to reference Kovacs J, Votava F, Heinze G, Solyom J, Lebl J, Pribilincova Z, Frisch H, Battelino T, Waldhauser F. Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries. J Clin Endocrinol Metab. 2001;86(7):2958–64.PubMed Kovacs J, Votava F, Heinze G, Solyom J, Lebl J, Pribilincova Z, Frisch H, Battelino T, Waldhauser F. Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries. J Clin Endocrinol Metab. 2001;86(7):2958–64.PubMed
25.
go back to reference Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, Rogol AD, Van Wyk JJ, Bornstein SR. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med. 2000;343(19):1362–8.CrossRefPubMed Merke DP, Chrousos GP, Eisenhofer G, Weise M, Keil MF, Rogol AD, Van Wyk JJ, Bornstein SR. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med. 2000;343(19):1362–8.CrossRefPubMed
26.
go back to reference Tutunculer F, Saka N, Arkaya SC, Abbasoglu S, Bas F. Evaluation of adrenomedullary function in patients with congenital adrenal hyperplasia. Horm Res. 2009;72(6):331–6.PubMed Tutunculer F, Saka N, Arkaya SC, Abbasoglu S, Bas F. Evaluation of adrenomedullary function in patients with congenital adrenal hyperplasia. Horm Res. 2009;72(6):331–6.PubMed
27.
go back to reference Green-Golan L, Yates C, Drinkard B, Van Ryzin C, Eisenhofer G, Weise M, Merke DP. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glycemic control during prolonged moderate-intensity exercise. J Clin Endocrinol Metab. 2007;92(8):3019–24.CrossRefPubMed Green-Golan L, Yates C, Drinkard B, Van Ryzin C, Eisenhofer G, Weise M, Merke DP. Patients with classic congenital adrenal hyperplasia have decreased epinephrine reserve and defective glycemic control during prolonged moderate-intensity exercise. J Clin Endocrinol Metab. 2007;92(8):3019–24.CrossRefPubMed
28.
go back to reference Meyburg J, Bernhard M, Hoffmann GF, Motsch J. Principles of pediatric emergency care. Deutsches Arzteblatt Int. 2009;106(45):739–47. quiz 748 Meyburg J, Bernhard M, Hoffmann GF, Motsch J. Principles of pediatric emergency care. Deutsches Arzteblatt Int. 2009;106(45):739–47. quiz 748
29.
go back to reference Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab. 2011;96(6):E925–8.CrossRefPubMed Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab. 2011;96(6):E925–8.CrossRefPubMed
30.
go back to reference Von Petrykowski W, Abel M, Brämswig J: Schweres Hirnödem - eine wenig bekannte Manifestation des Glukokortikoidmangels. Pädiatrische Praxis 1986/87, 34:5. Von Petrykowski W, Abel M, Brämswig J: Schweres Hirnödem - eine wenig bekannte Manifestation des Glukokortikoidmangels. Pädiatrische Praxis 1986/87, 34:5.
31.
go back to reference Walsh FB. Papilledema associated with increased intracranial pressure in Addison's disease. AMA. Arch Ophthalmol. 1952;47(1):86.CrossRef Walsh FB. Papilledema associated with increased intracranial pressure in Addison's disease. AMA. Arch Ophthalmol. 1952;47(1):86.CrossRef
32.
go back to reference Swingle WW, Pfiffner JJ, Vars HM, Bott PA, Parkins WM. The function of the adrenal cortical hormone and the cause of death from adrenal insufficiency. Science. 1933;77(1985):58–64.CrossRefPubMed Swingle WW, Pfiffner JJ, Vars HM, Bott PA, Parkins WM. The function of the adrenal cortical hormone and the cause of death from adrenal insufficiency. Science. 1933;77(1985):58–64.CrossRefPubMed
33.
go back to reference Swingle WW, Swingle AJ. Effect of adrenal steroids upon plasma volume of intact and Adrenalectomized dogs. Proc Soc Exp Biol Med. 1965;119:452–5.CrossRefPubMed Swingle WW, Swingle AJ. Effect of adrenal steroids upon plasma volume of intact and Adrenalectomized dogs. Proc Soc Exp Biol Med. 1965;119:452–5.CrossRefPubMed
34.
go back to reference Salpietro V, Polizzi A, Di Rosa G, Romeo AC, Dipasquale V, Morabito P, Chirico V, Arrigo T, Ruggieri M. Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications. Int J Endocrinol 2014. 2014:282489. https://doi.org/10.1155/2014/282489. Salpietro V, Polizzi A, Di Rosa G, Romeo AC, Dipasquale V, Morabito P, Chirico V, Arrigo T, Ruggieri M. Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications. Int J Endocrinol 2014. 2014:282489. https://​doi.​org/​10.​1155/​2014/​282489.
35.
go back to reference Zieg J. Pathophysiology of hyponatremia in children. Frontiers in Pediatr. 2017;5:213.CrossRef Zieg J. Pathophysiology of hyponatremia in children. Frontiers in Pediatr. 2017;5:213.CrossRef
Metadata
Title
Mortality in children with classic congenital adrenal hyperplasia and 21-hydroxylase deficiency (CAH) in Germany
Authors
Helmuth G. Dörr
Hartmut A. Wollmann
Berthold P. Hauffa
Joachim Woelfle
on behalf of the German Society of Pediatric Endocrinology and Diabetology
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2018
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-018-0263-1

Other articles of this Issue 1/2018

BMC Endocrine Disorders 1/2018 Go to the issue